Alpha Tau Medical (DRTS) Long-Term Deferred Tax (2020 - 2025)

Alpha Tau Medical (DRTS) reported Long-Term Deferred Tax of $97000.0 for Q4 2025, down 97.45% sequentially from $3.8 million in Q4 2021.

Alpha Tau Medical (DRTS) Long-Term Deferred Tax (2020 - 2025) Analysis & Trends

Alpha Tau Medical (DRTS) has 3 years of Long-Term Deferred Tax data on file, last reported at $97000.0 in Q4 2025.

For the quarter ending Q4 2025, Long-Term Deferred Tax changed N/A year-over-year to $97000.0; the trailing twelve-month figure through Dec 2025 stood at $97000.0 (changed N/A YoY), and the FY2025 full-year result was $97000.0, changed N/A from the prior year.
Long-Term Deferred Tax slipped to $97000.0 in Q4 2025, from $3.8 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $3.8 million in Q4 2021 to a low of $97000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alpha Tau Medical	1.12 Bn	1.04 Bn	-

Download Data